Literature DB >> 6969347

Quality of survival in histiocytosis X: a Southwest Oncology Group study.

D M Komp, A El Mahdi, K A Starling, J Easley, T J Vietti, D H Berry, S L George.   

Abstract

Sixty children survived for five years after the diagnosis of histiocytosis X. Serious disabilities were seen in 50% of children whose disease involved soft tissue and bone. Late deaths from pulmonary failure were associated with opportunistic infections in two cases. Future treatment approaches must weigh the risks of therapy-related complications against the probability of significant disability if the disease continues for many years.

Entities:  

Mesh:

Year:  1980        PMID: 6969347     DOI: 10.1002/mpo.2950080106

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  Favourable prognostic features in histiocytosis X: bone involvement and absence of skin disease.

Authors:  V Broadbent
Journal:  Arch Dis Child       Date:  1986-12       Impact factor: 3.791

2.  Histiocytosis X--current controversies.

Authors:  V Broadbent; J Pritchard
Journal:  Arch Dis Child       Date:  1985-07       Impact factor: 3.791

3.  Progressive spinocerebellar degeneration "plus" associated with Langerhans cell histiocytosis: a new paraneoplastic syndrome?

Authors:  H Goldberg-Stern; R Weitz; R Zaizov; M Gornish; N Gadoth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

4.  Langerhans cell histiocytosis--clinical and epidemiological aspects.

Authors:  V Broadbent; R M Egeler; M E Nesbit
Journal:  Br J Cancer Suppl       Date:  1994-09

Review 5.  Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review.

Authors:  Elgida Radoncipi Volpicelli; Leona Doyle; Justin P Annes; Michael F Murray; Eric Jacobsen; George F Murphy; Arturo P Saavedra
Journal:  J Cutan Pathol       Date:  2010-12-12       Impact factor: 1.587

Review 6.  Treatment of Langerhans cell histiocytosis--evolution and current approaches.

Authors:  S Ladisch; H Gadner
Journal:  Br J Cancer Suppl       Date:  1994-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.